...
机译:OA05.03单孕roralpituzubab tesirine,一种Δδ样蛋白3(dll3) - 小细胞肺癌(SCLC)中的抗体 - 药物缀合物(ADC)
Sarah Cannon Research Institute/tennessee Oncology;
Memorial Sloan Kettering Cancer Center;
Sarah Cannon Research Institute/tennessee Oncology;
Duke University Medical Center;
Washington University School of Medicine in St. Louis;
The University of Texas MD Anderson Cancer Center;
The University of Texas MD Anderson Cancer Center;
Sarah Cannon Research Institute/tennessee Oncology;
Sarah Cannon Research Institute/tennessee Oncology;
University of Alabama - Birmingham;
Abbvie Stemcentrx Llc;
Abbvie Stemcentrx Llc;
Roche Diagnostics;
Roche Diagnostics;
Roche Diagnostics;
Roche Diagnostics;
Tennessee Oncology PLCC Sarah Cannon Research Institute;
Abbvie Stemcentrx Llc;
Abbvie Stemcentrx Llc;
Abbvie Stemcentrx Llc;
Washington University School of Medicine in St. Louis;
Medicine Memorial Sloan Kettering Cancer Center;
机译:OA05.03单孕roralpituzubab tesirine,一种Δδ样蛋白3(dll3) - 小细胞肺癌(SCLC)中的抗体 - 药物缀合物(ADC)
机译:ROPARPITUZUMABAB Teesirine抗体 - 药物缀合物靶向δ样蛋白3(DLL3)小细胞肺癌治疗
机译:ROPALPITUZUMAB毒素,一种抗体 - 药物缀合物,中小细胞肺癌研究中的抗体 - 药物缀合物的Lepulation药代动力学
机译:靶向人癌细胞上的MUC1-C癌蛋白的抗体 - 药物缀合物的研制
机译:抗-Muc1抗体-药物结合物对靶癌症特异性的发展。
机译:Rovalpituzumab tesirine一种针对DLL3的抗体-药物偶联物在复发性小细胞肺癌中的应用:一项人类首次开创性开放标签的1期研究
机译:OA05.03单孕酮ROValPituzuabab Teesirine,一种类似的蛋白质3(DLL3) - 小细胞肺癌(SCLC)中的抗体 - 药物缀合物(ADC)
机译:开发针对癌症治疗的药物靶向方法:药物载体 - 蛋白质缀合物。